^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Columvi (glofitamab-gxbm)

    i
    Other names: RG6026, RO7082859, CD20 TCB, RG 6026, RO-7082859, RO 7082859, anti-CD20 CD3 TCB, RG-6026
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    2d
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    4d
    C4971006: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (clinicaltrials.gov)
    P1/2, N=40, Terminated, Pfizer | N=30 --> 40 | Active, not recruiting --> Terminated; Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.
    Enrollment change • Trial termination
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
    10d
    NP30179: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=940, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> Mar 2029 | Trial primary completion date: Dec 2029 --> Mar 2029
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    14d
    CaDAnCe-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeOne Medicines
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Lunsumio (mosunetuzumab-axgb) • sonrotoclax (BGB-11417) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    14d
    Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics. (PubMed, Am J Hematol)
    Glofitamab demonstrates early clinical activity and measurable CNS penetration in R/R PCNSL. Serial CSF ctDNA profiling may aid treatment monitoring, warranting prospective validation.
    Journal • Real-world evidence • Circulating tumor DNA
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    16d
    Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) (clinicaltrials.gov)
    P2, N=40, Recruiting, University Health Network, Toronto | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial primary completion date • Circulating tumor DNA
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    18d
    A single-arm, prospective, phase II study of Glofitamab in combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin,and Prednisone (Pola-R-CHP) to optimize primary therapy in patients with high-risk Diffuse Large B-Cell Lymphoma assessed by interim FDG PET and ctDNA (ChiCTR2600118538)
    P2, N=42, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial • Circulating tumor DNA
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    18d
    A prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of glofitamab in combination with gemcitabine, dexamethasone, and cisplatin (Glofit-GDP) as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (ChiCTR2600116920)
    P=N/A, N=43, Recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • gemcitabine • dexamethasone • Columvi (glofitamab-gxbm)
    19d
    Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial
    |
    gemcitabine • oxaliplatin • Columvi (glofitamab-gxbm)
    24d
    Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • SP140 (SP140 Nuclear Body Protein) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Columvi (glofitamab-gxbm)
    25d
    Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed after, CAR T-cell therapy. (2025-523428-39-00)
    P1/2, N=41, Not yet recruiting, Fondazione Italiana Linfomi Ets
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    26d
    REBEL: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Utah
    New P1 trial
    |
    Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)